Deepbridge are pleased to announce that Manchester Biotech Ltd, which is supporting scientists to use bioprinting, liquid handling and 3D cell culture to develop new technologies that aim to improve patient lives, have now joined the Deepbridge Life Sciences EIS portfolio.
A total raise of up to £1.54m was recently agreed, which follows on from an initial seed funding round, through the Deepbridge Life Sciences SEIS portfolio.
By taking an active and hands-on approach, the Deepbridge life sciences team will be adding real value and knowledge to Manchester Biotech. This approach will seek to improve the likelihood of a successful exit, which will aim to provide an attractive return on investment to our investors.
About Manchester Biotech:
The Company develops formulated ready-to-use and easy-to-handle hydrogels that are primarily used in medical research laboratories.